GH Research PLC
Research GH Research PLC (GHRS) on Bullrun: market cap USD 1.98B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerGHRS
- ExchangeNASDAQ
- CountryIreland
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.98B
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 15.15M
- Free cash flow-USD 15.04M
Valuation Snapshot
latest market cap is USD 1.98B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 48.26M | -USD 43.67M | n/a | -1.36 | USD 246.25M | USD 512.00K | USD 279.70M |
| FY2024 | USD 0 | -USD 38.96M | -USD 42.33M | n/a | -1.33 | USD 100.79M | USD 624.00K | USD 178.95M |
| FY2023 | n/a | n/a | n/a | n/a | -1.15 | USD 78.42M | USD 974.00K | USD 218.97M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 1.98B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 787.77M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 364.20M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 301.72M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 505.64M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.21B | n/a | n/a | n/a |
About GH Research PLC
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is GH Research PLC's market cap?
GH Research PLC's market capitalization is USD 1.98B.
What does GH Research PLC do?
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression.